InMed Pharmaceuticalsの空売り状況は、投資家がInMed Pharmaceuticalsの株価下落に賭けている度合いを知ることができます。空売りデータは2週間ごとに更新されます。

InMed Pharmaceuticals (NASDAQ:INM) 株価情報, 空売り情報

InMed Pharmaceuticals

InMed Pharmaceuticals Inc is a Canada based clinical-stage biopharmaceutical company. The company is engaged in the research and development of novel, cannabinoid-based, and manufacturing of Pharmaceutical grade cannabinoids. Its product portfolio includes INM-755, which is used for the treatment of epidermolysis bullosa; INM-088 for the treatment of glaucoma; INM-901 for Alzheimer's disease, INM-089's pharmacological and IntegraSyn which is a manufacturing system for Pharmaceutical-Grade Cannabinoids.

InMed Pharmaceuticals Inc. - Common Shares

InMed Pharmaceuticals Inc

INmune Bio Inc

InMode Ltd

Inca Minerals Ltd

iShares Intermediate Muni Income Active ETF

Needham analyst Serge Belanger maintains Xenon Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/XENE#NASDAQ">XENE</a>) with a Buy and lowers the price target from $60 to $55.

News

Price Target

Analyst Ratings

XENE

Needham Maintains Buy on Xenon Pharmaceuticals, Lowers Price Target to $55

Health Care

General

GCTK

Glucotrack Receives Ethical Approval From St. Vincent's Hospital Melbourne Human Research Ethics Committee For Long-Term Clinical Study of Continuous Blood Glucose Monitor

Glucotrack Secures Ethical Approval From St. Vincent's Hospital Melbourne HREC For Long-Term Clinical Study Of CBGM In Participants With Type 1 And Type 2 Diabetes

Chanson International Holding (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CHSN#NASDAQ">CHSN</a>) (the "Company" or "Chanson"), a provider of bakery, seasonal, and beverage products through its chain stores in China and the United States, today announced that its self-developed "Songkang Meal" series of nasogastric nutrition formulas has received official registration approval as a Food for Special Medical Purpose ("FSMP") in China. The product has been adopted for use in several hospitals in Xinjiang. As the Company's first FSMP product, "Songkang Meal" represents Chanson's expansion into the medical nutrition and FSMP market, presenting an opportunity for new revenue streams.

Global

CHSN

Chanson International Secures Chinese FSMP Approval For Self-Developed "Songkang Meal" Nasogastric Nutrition Formula, Now Used In Xinjiang Hospitals

Contracts

JFB Construction Holdings Awarded $6.7M Contract As General Contractor For Courtyard By Marriott Conversion And Remodel

D. Boral Capital analyst Jesse Sobelson maintains FiscalNote Holdings (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NOTE#NYSE">NOTE</a>) with a Buy and maintains $3.75 price target.

NOTE

D. Boral Capital Maintains Buy on FiscalNote Holdings, Maintains $3.75 Price Target

Investment Will Support Leading Provider of Electric Utility Maintenance and Construction Services in its Mission to Address Growing US Power Demand and Needed Grid Improvements
HARTSELLE, Ala. and NEW YORK, May 13, 2025 (GLOBE NEWSWIRE) -- Apollo (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/APO#NYSE">APO</a>) today announced that Apollo-managed funds and affiliates associated with its hybrid strategies (the "Apollo Funds") have agreed to acquire a majority stake in PowerGrid Services ("PGS"), a leading provider of maintenance and construction services to electric utilities across the United States. The Apollo Funds will partner with existing PGS investors, including company management and The Sterling Group, to support PGS's continued growth.

Apollo Funds To Acquire Majority Stake In PowerGrid Services From The Sterling Group; Terms Not Disclosed

CGNT

Cognyte Wins ~$5M Contract With A Law Enforcement Agency Customer In EMEA Region

During times of turbulence and uncertainty in the markets, many investors turn to dividend-yielding stocks. These are often companies that have high free cash flows and reward shareholders with a<a href="https://www.benzinga.com/yield-investments"> high dividend payout</a>.
Benzinga readers can review the latest analyst takes on their favorite stocks by visiting <a href="https://www.benzinga.com/analyst-stock-ratings">Analyst Stock Ratings</a> page. Traders can sort through Benzinga's extensive database of analyst ratings, including <a href="https://www.benzinga.com/analyst-ratings/analyst-color/22/09/28888638/exclusive-study-finds-benzinga-analyst-ratings-data-yields-market-beating-strategie">by analyst accuracy</a>.
Below are the ratings of the most accurate analysts for three high-yielding stocks in the utilities sector.
<h3 class="wp-block-heading">Edison International (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/EIX#NYSE">EIX</a>)</h3>
<ul class="wp-block-list">
<li>Dividend Yield: 5.85%</li>
<li>Barclays analyst Nicholas Campanella maintained an Overweight rating and raised the price target from $64 to $67 on May 1, 2025. This analyst has an accuracy rate of 65%.</li>
<li>Morgan Stanley analyst David Arcaro maintained an Underweight rating and increased the price target from $48 to $52 on March 20, 2025. This analyst has an accuracy rate of 68%.</li>
<li>Recent News: On April 29, the company posted mixed quarterly results</li>
<li>Benzinga Pro&#8217;s real-time newsfeed alerted to <a href="https://www.benzinga.com/pro/register?utm_adType=bzprocontent&amp;utm_campaign=14daytrial&amp;utm_ad=0513">latest EIX news</a>. </li>
</ul>
<figure class="wp-block-image size-full is-resized"><a href=" https://www.benzinga.com/pro/register?utm_adType=bzprocontent&amp;utm_campaign=14daytrial&amp;utm_ad=0513"><img loading="lazy" decoding="async" width="917" height="812" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/05/13045142/image-138.png" alt="" class="wp-image-913125" style="width:509px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/05/13045142/image-138.png 917w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/05/13045142/image-138-300x266.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/05/13045142/image-138-768x680.png 768w" sizes="(max-width: 917px) 100vw, 917px" /></a></figure>
<h3 class="wp-block-heading">Portland General Electric Company (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/POR#NYSE">POR</a>)</h3>
<ul class="wp-block-list">
<li>Dividend Yield: 4.93%</li>
<li>Barclays analyst Nicholas Campanella maintained an Equal-Weight rating and cut the price target from $48 to $45 on April 30, 2025. This analyst has an accuracy rate of 65%.</li>
<li>Wells Fargo analyst Sarah Akers maintained an Equal-Weight rating and slashed the price target from $46 to $44 on April 28, 2025. This analyst has an accuracy rate of 70%.</li>
<li>Recent News: On April 25, Portland Gen Electric posted downbeat quarterly results.</li>
<li>Benzinga Pro's real-time newsfeed alerted to latest POR <a href="https://www.benzinga.com/pro/register?utm_adType=bzprocontent&amp;utm_campaign=14daytrial&amp;utm_ad=0513">news </a></li>
</ul>
<figure class="wp-block-image size-full is-resized"><a href=" https://www.benzinga.com/pro/register?utm_adType=bzprocontent&amp;utm_campaign=14daytrial&amp;utm_ad=0513"><img loading="lazy" decoding="async" width="893" height="822" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/05/13045217/image-139.png" alt="" class="wp-image-913127" style="width:534px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/05/13045217/image-139.png 893w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/05/13045217/image-139-300x276.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/05/13045217/image-139-768x707.png 768w" sizes="(max-width: 893px) 100vw, 893px" /></a></figure>
<h3 class="wp-block-heading">Northwest Natural Holding Company (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NWN#NYSE">NWN</a>)</h3>
<ul class="wp-block-list">
<li>Dividend Yield: 4.75%</li>
<li>Wells Fargo analyst Sarah Akers maintained an Equal-Weight rating and raised the price target from $45 to $47 on May 7, 2025. This analyst has an accuracy rate of 70%.</li>
<li>Janney Montgomery analyst Michael Gaugler upgraded the stock from Neutral to Buy and boosted the price target from $36 to $43 on Aug. 5, 2024. This analyst has an accuracy rate of 73%.</li>
<li>Recent News: On May 6, Northwest Natural posted better-than-expected quarterly results.</li>
<li>Benzinga Pro&#8217;s real-time newsfeed alerted to latest NWN <a href="https://www.benzinga.com/pro/register?utm_adType=bzprocontent&amp;utm_campaign=14daytrial&amp;utm_ad=0513">news </a></li>
</ul>
<figure class="wp-block-image size-full is-resized"><a href=" https://www.benzinga.com/pro/register?utm_adType=bzprocontent&amp;utm_campaign=14daytrial&amp;utm_ad=0513"><img loading="lazy" decoding="async" width="908" height="822" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/05/13045257/image-140.png" alt="" class="wp-image-913130" style="width:520px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/05/13045257/image-140.png 908w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/05/13045257/image-140-300x272.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/05/13045257/image-140-768x695.png 768w" sizes="(max-width: 908px) 100vw, 908px" /></a></figure>
<figure class="wp-block-embed is-type-video is-provider-youtube wp-block-embed-youtube wp-embed-aspect-16-9 wp-has-aspect-ratio"> 
<div class="wp-block-embed__wrapper">
<iframe loading="lazy" title="How to Find Dividend Stocks: Scan, Analyze, and Capture with Benzinga Pro" width="500" height="281" src="https://www.youtube.com/embed/pVF0O2lsEH4?start=1&#038;feature=oembed" frameborder="0" allow="accelerometer; autoplay; clipboard-write; encrypted-media; gyroscope; picture-in-picture; web-share" referrerpolicy="strict-origin-when-cross-origin" allowfullscreen></iframe>
</div>
</figure>
Read More:
<ul class="wp-block-list">
<li> <a href="https://www.benzinga.com/news/earnings/25/05/45368490/under-armour-cyberark-software-and-3-stocks-to-watch-heading-into-tuesday">Under Armour, CyberArk Software And 3 Stocks To Watch Heading Into Tuesday</a> </li>
</ul>
Photo via Shutterstock

Dividends

Pre-Market Outlook

Markets

Trading Ideas

Wall Street's Most Accurate Analysts Give Their Take On 3 Utilities Stocks With Over 4% Dividend Yields

HC Wainwright &amp; Co. analyst Yi Chen reiterates BioLife Solutions (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BLFS#NASDAQ">BLFS</a>) with a Buy and maintains $30 price target.

Reiteration

BLFS

HC Wainwright & Co. Reiterates Buy on BioLife Solutions, Maintains $30 Price Target

Quoin Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/QNRX#NASDAQ">QNRX</a>) reported quarterly losses of $(6.50) per share which missed the analyst consensus estimate of $(6.07) by 7.08 percent. This is a 83.22 percent increase over losses of $(38.73) per share from the same period last year.

Earnings

Earnings Misses

QNRX

Quoin Pharmaceuticals Q1 EPS $(6.50) Misses $(6.07) Estimate

VerifyMe (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VRME#NASDAQ">VRME</a>) reported quarterly losses of $(0.05) per share which beat the analyst consensus estimate of $(0.07) by 28.57 percent. This is unchanged from the same period last year. The company reported quarterly sales of $4.46 million which missed the analyst consensus estimate of $5.09 million by 12.50 percent. This is a 22.64 percent decrease over sales of $5.76 million the same period last year.

Earnings Beats

VRME

VerifyMe Q1 EPS $(0.05) Beats $(0.07) Estimate, Sales $4.46M Miss $5.09M Estimate

<a href="https://www.benzinga.com/quote/HOOD/analyst-ratings">Robinhood Markets, Inc.</a> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HOOD#NASDAQ">HOOD</a>) has signed an agreement to acquire WonderFi Technologies Inc., a Canadian cryptocurrency platform, in an all-cash transaction valued at approximately $178 million.
What Happened: The purchase price of $0.26 per share represents a 41 percent premium over WonderFi's closing price on May 12 and a 71 percent premium over its 30-day volume-weighted average price, according to a company <a href="https://newsroom.aboutrobinhood.com/robinhood-to-acquire-wonderfi/">statement</a>.
WonderFi operates Bitbuy and Coinsquare, two regulated cryptocurrency exchanges in Canada, with a reported $1.49 billion in assets under custody. 
The company will continue operating its platforms after the transaction closes. 
The deal is expected to be completed in the second half of 2025, subject to shareholder approval, regulatory review and court authorization.
Robinhood, which opened a Canadian headquarters in Toronto in 2024, will incorporate WonderFi's operations into its existing crypto business. 
According to the agreement, WonderFi's leadership team is expected to remain with the company following the acquisition. 
Employees will be added to Robinhood's Canadian workforce, which currently includes over 140 people.
Also Read: <a href="https://www.benzinga.com/markets/cryptocurrency/25/05/45371362/coinbase-could-see-up-to-16b-net-inflows-after-sp-500-entry-bernstein">Coinbase Could See Up To $16B Net Inflows After S&amp;P 500 Entry: Bernstein</a>
The acquisition will be carried out under a statutory plan of arrangement governed by British Columbia corporate law. 
Robinhood plans to fund the purchase using existing cash reserves. No stock issuance or debt financing will be used to support the transaction.
WonderFi shareholders will receive the full purchase amount in cash. 
The company's common shares are currently listed on the Toronto Stock Exchange. The combined equity value of the transaction, on a fully diluted basis, stands at approximately $178 million.
Advisors on the deal include J.P. Morgan Securities for Robinhood and Financial Technology Partners for WonderFi. 
Legal counsel was provided by Canadian firms on both sides, including Goodmans LLP, Cassels Brock &amp; Blackwell LLP, and Mintz LLP.
Read Next: 
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/markets/cryptocurrency/25/05/45356864/cardano-up-23-in-7-days-as-co-founder-charles-hoskinson-explores-privacy-focused-stablecoin">Cardano Up 23% In 7 Days As Co-Founder Charles Hoskinson Explores Privacy-Focused Stablecoin</a></li>
</ul>
Image: Shutterstock

Coverage of Bitcoin, Etherum, Ripple and all the latest digital currencies.

Cryptocurrency

HOOD

Robinhood To Acquire Canada's WonderFi For $178M All-Cash Deal

Intelligent Bio Solutions Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INBS#NASDAQ">INBS</a>) on Tuesday reported a third quarter 2025 loss of 44 cents per share, down from a <a target="_blank" href="https://www.benzinga.com/calendars/earnings" rel="noreferrer noopener">loss of $1.43 a year ago</a>.
The noninvasive testing solutions provider reported sales of $728.87 thousand, down from $823.80 thousand a year ago.
Total revenues increased 20% quarter-over-quarter, supported by ongoing expansion across safety-critical industries and <a target="_blank" href="https://www.benzinga.com/general/health-care" rel="noreferrer noopener">steady customer acquisition</a>.
Also Read: <a target="_blank" href="https://www.benzinga.com/general/health-care/25/03/44472191/exclusive-fda-seeks-additional-information-for-intelligent-bio-solutions-drug-screening-system-clearance-process-remains-on-track-for-2025-us-launch" rel="noreferrer noopener">EXCLUSIVE: FDA Seeks Additional Information For Intelligent Bio Solutions' Drug Screening System, Clearance Process Remains on Track For 2025 US Launch</a>
As we expand further into new markets, our focus on growing cartridge adoption, our highest-margin revenue stream, is strengthening the business fundamentals," said Harry Simeonidis, President and CEO at Intelligent Bio Solutions.
"We've also seen a notable reduction in losses this quarter, reflecting ongoing improvements in cost control and operational efficiency. To support global scalability, we introduced multilingual functionality across our drug screening system and websites, ensuring our solution is widely accessible, commercially viable, and ready for broader distribution across international markets. We believe these efforts are laying a strong foundation for long-term, sustainable revenue growth."
The company secured 35 new accounts during the quarter ended March 31, 2025, bringing its total active account base to over 450.
Cartridge revenue increased from 49% to 58% for the nine months ended March 31, 2025, an increase of 9 percentage points compared to the same period in 2024.
As of March 31, 2025, total cash and cash equivalents were $2.81 million.&nbsp;
Gross profits for the fiscal third quarter were $341,368, an increase of 91% year-over-year.
Increases in gross profit are mainly attributable to enhanced production capacity, which has reduced direct labor, direct materials, and direct product-related overhead costs.
The company said it continues to improve its strategic sales mix and operational streamlining, thus driving increased gross profit.&nbsp;
Net loss attributable to the company decreased to $2.54 million from $2.98 million a year ago.
During the fiscal third quarter, the company advanced its international growth strategy and product readiness through a series of targeted initiatives. These included expanded access in key European markets, multilingual upgrades to its drug screening system and digital outlets, and further protection of its core intellectual property portfolio. Intelligent Bio said these developments support its ability to scale globally and drive sustained commercial growth.
In March, Intelligent Bio received a U.S. patent for its Intelligent <a target="_blank" href="https://www.benzinga.com/general/health-care/25/03/44491787/exclusive-intelligent-bio-solutions-adds-sixth-us-patent-for-its-drug-screening-technology" rel="noreferrer noopener">Fingerprinting Drug Screening Cartridge</a>.&nbsp;
This&nbsp;is the company's sixth active patent to be granted in the U.S., strengthening the protection of its unique and proprietary drug screening technology.&nbsp;
U.S. Patent (12259385)&nbsp;relates to the proprietary lateral flow test strip inside the company's Drug Screening Cartridge.
Price Action: At the last check on Tuesday, INBS stock was up 4.92% at $1.28 during the premarket session.
Read Next:
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/general/biotech/25/05/45371916/exclusive-alzamend-neuro-initiates-first-phase-2-trial-of-lead-program-in-healthy-human-participants" target="_blank" rel="noreferrer noopener">EXCLUSIVE: Alzamend Neuro Initiates First Phase 2 Trial Of Lead Program In Healthy Human Participants</a></li>
</ul>

Market-Moving Exclusives

Exclusives

Movers

Intelligent Bio Solutions Inc. - Common Stock

INBS

EXCLUSIVE: Intelligent Bio Solutions Q3 Gross Profit Jumps By 91%

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades, downgrades and initiations, please see our <a href="https://www.benzinga.com/analyst-stock-ratings">analyst ratings page</a>.
<ul class="wp-block-list">
<li>Compass Point analyst Merrill Ross downgraded the rating for Independence Realty Trust, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/IRT#NYSE">IRT</a>) from Buy to Neutral and announced a $22 price target. Independence Realty Trust shares closed at $19.31 on Monday. <a href="https://www.benzinga.com/quote/IRT/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>DA Davidson analyst Rudy Kessinger downgraded the rating for Rapid7, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RPD#NASDAQ">RPD</a>) from Neutral to Underperform and lowered the price target from $29 to $21. Rapid7 shares closed at $26.74 on Monday. <a href="https://www.benzinga.com/quote/RPD/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Compass Point analyst Merrill Ross downgraded NexPoint Residential Trust, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NXRT#NYSE">NXRT</a>) from Buy to Neutral and slashed the price target from $50 to $42.5. NexPoint Residential shares closed at $37.53 on Monday. <a href="https://www.benzinga.com/quote/NXRT/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Leerink Partners analyst Daina Graybosch downgraded Affimed N.V. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AFMD#NASDAQ">AFMD</a>) from Outperform to Market Perform and cut the price target from $5 to $0.39. Affimed shares closed at $0.6930 on Monday. <a href="https://www.benzinga.com/quote/AFMD/analyst-ratings">See how other analysts view this stock</a>.</li>
</ul>
Considering buying RPD stock? Here&#8217;s what analysts think: 
<figure class="wp-block-image size-large is-resized"><img loading="lazy" decoding="async" width="1024" height="576" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/05/13075757/image-142-1024x576.png" alt="" class="wp-image-913351" style="width:633px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/05/13075757/image-142-1024x576.png 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/05/13075757/image-142-300x169.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/05/13075757/image-142-768x432.png 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/05/13075757/image-142.png 1095w" sizes="(max-width: 1024px) 100vw, 1024px" /></figure>
Read This Next: 
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/news/earnings/25/05/45368490/under-armour-cyberark-software-and-3-stocks-to-watch-heading-into-tuesday">Under Armour, CyberArk Software And 3 Stocks To Watch Heading Into Tuesday</a> </li>
</ul>
Photo via Shutterstock

Downgrades

AFMD

NXRT

This Rapid7 Analyst Turns Bearish; Here Are Top 4 Downgrades For Tuesday

Throughout the last three months, 4 analysts have evaluated Indie Semiconductor (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INDI#NASDAQ">INDI</a>), offering a diverse set of opinions from bullish to bearish.
The table below provides a snapshot of their recent ratings, showcasing how sentiments have evolved over the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">3</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
Analysts' evaluations of 12-month price targets offer additional insights, showcasing an average target of $7.25, with a high estimate of $8.00 and a low estimate of $6.00. A decline of 12.12% from the prior average price target is evident in the current average. 
<img src="https://www.benzinga.com/files/images/story/2025/1747137639_0.png" alt="price target chart" />
<h2>Exploring Analyst Ratings: An In-Depth Overview</h2>
A clear picture of Indie Semiconductor's perception among financial experts is painted with a thorough analysis of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Cody Acree</td>
<td>Benchmark</td>
<td>Lowers</td>
<td>Buy</td>
<td>$6.00</td>
<td>$8.00</td>
</tr>
<tr>
<td>Cody Acree</td>
<td>Benchmark</td>
<td>Maintains</td>
<td>Buy</td>
<td>$8.00</td>
<td>$8.00</td>
</tr>
<tr>
<td>John Vinh</td>
<td>Keybanc</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$7.00</td>
<td>$8.00</td>
</tr>
<tr>
<td>Cody Acree</td>
<td>Benchmark</td>
<td>Lowers</td>
<td>Buy</td>
<td>$8.00</td>
<td>$9.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts frequently update their recommendations based on evolving market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to Indie Semiconductor. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Unveiling insights, analysts deliver qualitative insights into stock performance, from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of Indie Semiconductor compared to the broader market.</li>
<li>Price Targets: Understanding forecasts, analysts offer estimates for Indie Semiconductor's future value. Examining the current and prior targets provides insight into analysts' changing expectations.</li>
</ul>
Understanding these analyst evaluations alongside key financial indicators can offer valuable insights into Indie Semiconductor's market standing. Stay informed and make well-considered decisions with our Ratings Table.
<a href="https://www.benzinga.com/quote/INDI/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Stay up to date on Indie Semiconductor analyst ratings.</a>
If you are interested in following small-cap stock news and performance <a href="https://www.benzinga.com/news/small-cap?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">you can start by tracking it here</a>.
<h2>Discovering Indie Semiconductor: A Closer Look</h2>
Indie Semiconductor Inc is empowering the Autotech revolution with next-generation automotive semiconductors and software platforms. It focuses on edge sensors for advanced Driver Assistance Systems including LiDAR, connected car, user experience, and electrification applications. These technologies represent the core underpinnings of both electric and autonomous vehicles, while the advanced user interfaces transform the in-cabin experience to mirror and seamlessly connect to the mobile platforms. Geographically, the company generates majority of its revenue from Greater China and rest from United States, Europe, South Korea and other regions.
<h3>Financial Milestones: Indie Semiconductor's Journey</h3>
Market Capitalization Analysis: Positioned below industry benchmarks, the company's market capitalization faces constraints in size. This could be influenced by factors such as growth expectations or operational capacity.
Decline in Revenue: Over the 3M period, Indie Semiconductor faced challenges, resulting in a decline of approximately -17.29% in revenue growth as of 31 December, 2024. This signifies a reduction in the company's top-line earnings. In comparison to its industry peers, the company trails behind with a growth rate lower than the average among peers in the Information Technology sector.
Net Margin: The company's net margin is below industry benchmarks, signaling potential difficulties in achieving strong profitability. With a net margin of -56.17%, the company may need to address challenges in effective cost control.
Return on Equity (ROE): The company's ROE is below industry benchmarks, signaling potential difficulties in efficiently using equity capital. With an ROE of -7.43%, the company may need to address challenges in generating satisfactory returns for shareholders.
Return on Assets (ROA): The company's ROA is below industry benchmarks, signaling potential difficulties in efficiently utilizing assets. With an ROA of -3.75%, the company may need to address challenges in generating satisfactory returns from its assets.
Debt Management: With a below-average debt-to-equity ratio of 0.95, Indie Semiconductor adopts a prudent financial strategy, indicating a balanced approach to debt management.
<h2>How Are Analyst Ratings Determined?</h2>
Within the domain of banking and financial systems, analysts specialize in reporting for specific stocks or defined sectors. Their work involves attending company conference calls and meetings, researching company financial statements, and communicating with insiders to publish "analyst ratings" for stocks. Analysts typically assess and rate each stock once per quarter.
Some analysts also offer predictions for helpful metrics such as earnings, revenue, and growth estimates to provide further guidance as to what to do with certain tickers. It is important to keep in mind that while stock and sector analysts are specialists, they are also human and can only forecast their beliefs to traders.
Which Stocks Are Analysts Recommending Now?
Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9arja3be22bz21&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Click here to stay ahead of the market</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

INDI

Beyond The Numbers: 4 Analysts Discuss Indie Semiconductor Stock

Throughout the last three months, 4 analysts have evaluated NexPoint Residential (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NXRT#NYSE">NXRT</a>), offering a diverse set of opinions from bullish to bearish.
Summarizing their recent assessments, the table below illustrates the evolving sentiments in the past 30 days and compares them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">3</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
Analysts have recently evaluated NexPoint Residential and provided 12-month price targets. The average target is $42.88, accompanied by a high estimate of $44.00 and a low estimate of $42.00. Highlighting a 5.76% decrease, the current average has fallen from the previous average price target of $45.50. 
<img src="https://www.benzinga.com/files/images/story/2025/1747137626_0.png" alt="price target chart" />
<h2>Decoding Analyst Ratings: A Detailed Look</h2>
A clear picture of NexPoint Residential's perception among financial experts is painted with a thorough analysis of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Merrill Ross</td>
<td>Compass Point</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$42.50</td>
<td>$50.00</td>
</tr>
<tr>
<td>Buck Horne</td>
<td>Raymond James</td>
<td>Lowers</td>
<td>Outperform</td>
<td>$44.00</td>
<td>$50.00</td>
</tr>
<tr>
<td>Linda Tsai</td>
<td>Jefferies</td>
<td>Raises</td>
<td>Hold</td>
<td>$43.00</td>
<td>$41.00</td>
</tr>
<tr>
<td>Michael Lewis</td>
<td>Truist Securities</td>
<td>Raises</td>
<td>Hold</td>
<td>$42.00</td>
<td>$41.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts respond to changes in market conditions and company performance, frequently updating their recommendations. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to NexPoint Residential. This information offers a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Offering insights into predictions, analysts assign qualitative values, from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of NexPoint Residential compared to the broader market.</li>
<li>Price Targets: Analysts navigate through adjustments in price targets, providing estimates for NexPoint Residential's future value. Comparing current and prior targets offers insights into analysts' evolving expectations.</li>
</ul>
Assessing these analyst evaluations alongside crucial financial indicators can provide a comprehensive overview of NexPoint Residential's market position. Stay informed and make well-judged decisions with the assistance of our Ratings Table.
<a href="https://www.benzinga.com/quote/NXRT/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Stay up to date on NexPoint Residential analyst ratings.</a>
If you are interested in following small-cap stock news and performance <a href="https://www.benzinga.com/news/small-cap?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">you can start by tracking it here</a>.
<h2>All You Need to Know About NexPoint Residential</h2>
NexPoint Residential Trust Inc is a real estate investment trust company. Its objectives are to maximize the cash flow and value of properties owned, acquire properties with cash flow growth potential, provide quarterly cash distributions, and achieve long-term capital appreciation for stockholders. The company seeks to achieve these objectives through targeted management and a capex value-add program. It focuses on acquiring multifamily properties in markets with attractive job growth and household formation fundamentals predominantly in the Southeastern and Southwestern United States. The company generates revenue from the rental of multifamily properties.
<h3>NexPoint Residential: Financial Performance Dissected</h3>
Market Capitalization Perspectives: The company's market capitalization falls below industry averages, signaling a relatively smaller size compared to peers. This positioning may be influenced by factors such as perceived growth potential or operational scale.
Decline in Revenue: Over the 3M period, NexPoint Residential faced challenges, resulting in a decline of approximately -6.45% in revenue growth as of 31 March, 2025. This signifies a reduction in the company's top-line earnings. As compared to its peers, the revenue growth lags behind its industry peers. The company achieved a growth rate lower than the average among peers in Real Estate sector.
Net Margin: NexPoint Residential's net margin lags behind industry averages, suggesting challenges in maintaining strong profitability. With a net margin of -10.91%, the company may face hurdles in effective cost management.
Return on Equity (ROE): The company's ROE is below industry benchmarks, signaling potential difficulties in efficiently using equity capital. With an ROE of -1.75%, the company may need to address challenges in generating satisfactory returns for shareholders.
Return on Assets (ROA): NexPoint Residential's ROA lags behind industry averages, suggesting challenges in maximizing returns from its assets. With an ROA of -0.36%, the company may face hurdles in achieving optimal financial performance.
Debt Management: The company faces challenges in debt management with a debt-to-equity ratio higher than the industry average. With a ratio of 3.86, caution is advised due to increased financial risk.
<h2>Analyst Ratings: What Are They?</h2>
Ratings come from analysts, or specialists within banking and financial systems that report for specific stocks or defined sectors (typically once per quarter for each stock). Analysts usually derive their information from company conference calls and meetings, financial statements, and conversations with important insiders to reach their decisions.
Beyond their standard evaluations, some analysts contribute predictions for metrics like growth estimates, earnings, and revenue, furnishing investors with additional guidance. Users of analyst ratings should be mindful that this specialized advice is shaped by human perspectives and may be subject to variability.
Breaking: Wall Street's Next Big Mover
Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantag">Click here for urgent details</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Beyond The Numbers: 4 Analysts Discuss NexPoint Residential Stock

EXCLUSIVE: Intelligent Bio Solutions Tells Benzinga 'Gross profits for the fiscal third quarter were $341,368, an increase of 91% year-over-year'

EXCLUSIVE: Intelligent Bio Solutions Tells Benzinga 'Total revenues for the fiscal third quarter were $0.73 million, an increase of 20% quarter-over-quarter'

WIIM

NMRA

Neumora Therapeutics shares are trading higher. The company reported Q1 financial results.

Press Releases

Presenting on the Emerging Growth Conference 72 Day 1 on June 12 Register Now

Presenting on the Emerging Growth Conference 72 Day 2 on June 13 Register Now

The Rising Importance Of Minor Cannabinoids In The Growing Edible Market

InMed Demonstrates Encouraging Data For Its Cannabinoid INM-089 In Treating Dry AMD, An Ocular Disease With Rising Patient Numbers As National Population Ages

AAWH

ASPI

ATRA

BIXT

CLNN

CSE:KASH

CSE:TEX

CVKD

DBMM

FBRKF

GTRIF

IMRN

KASHF

LGMK

LGVN

MHUA

PERF

PSRHF

RERE

RGBP

SNES

SUGCF

TRGEF

TSXV:PLSR

TSXV:SUG

UMAC

Screenshot 2024-08-27 at 5.44.40 PM

Biotech

Screenshot 2024-07-18 at 5.31.04 PM

Cannabis

Screenshot 2024-05-06 at 5.34.20 PM

InMed (NASDAQ: INM) Developing Cannabinoids Analogs To Treat Alzheimer&#39;s – New Studies Showcase INM-901&#39;s Therapeutic Abilities

Comments

InMed Pharmaceuticals

空売り

InMed Pharmaceuticals (NASDAQ:INM) 株価情報, 空売り情報

ニュース

パートナーシップ

ベンジンガ・グローバル